Rapport Therapeutics (NASDAQ:RAPP) Director Ramiro Sanchez Buys 3,600 Shares of Company Stock

Rapport Therapeutics, Inc. (NASDAQ:RAPP) Director Ramiro Sanchez purchased 3,600 shares of Rapport Therapeutics stock in a transaction dated Friday, October 23rd. The shares were acquired at an average cost of $27.35 per share, with a total value of $98,460.00. Following the transaction, the director directly owned 3,600 shares in the company, valued at approximately $98,460. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Rapport Therapeutics Price Performance

Shares of NASDAQ:RAPP traded down $0.60 during trading on Friday, hitting $25.93. The company’s stock had a trading volume of 1,180,713 shares, compared to its average volume of 410,900. The company has a 50-day moving average of $39.44 and a 200-day moving average of $39.02. Rapport Therapeutics, Inc. has a 12 month low of $23.75 and a 12 month high of $52.93. The firm has a market cap of $1.24 billion, a price-to-earnings ratio of -8.53 and a beta of 1.22.

Rapport Therapeutics (NASDAQ:RAPP) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($1.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.07). As a group, research analysts anticipate that Rapport Therapeutics, Inc. will post -4.09 earnings per share for the current year.

Wall Street Analyst Weigh In

RAPP has been the subject of a number of recent research reports. Wolfe Research started coverage on shares of Rapport Therapeutics in a research report on Thursday, October 15th. They set an “outperform” rating and a $50.00 price objective for the company. Citigroup reaffirmed an “outperform” rating on shares of Rapport Therapeutics in a report on Tuesday. HC Wainwright reiterated a “buy” rating and set a $66.00 target price on shares of Rapport Therapeutics in a research report on Tuesday. UBS Group began coverage on Rapport Therapeutics in a report on Thursday, October 15th. They set a “buy” rating and a $71.00 price target for the company. Finally, JonesTrading upped their price target on Rapport Therapeutics from $50.00 to $82.00 and gave the stock a “buy” rating in a research report on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $68.36.

Institutional Trading of Rapport Therapeutics

Institutional investors have recently made changes to their positions in the business. Sterling Capital Management LLC lifted its holdings in shares of Rapport Therapeutics by 597.9% in the third quarter. Sterling Capital Management LLC now owns 984 shares of the company’s stock worth $33,000 after buying an additional 843 shares in the last quarter. Engineers Gate Manager LP purchased a new position in Rapport Therapeutics during the second quarter valued at $888,000. Wellington Management Group LLP grew its stake in Rapport Therapeutics by 11.2% during the second quarter. Wellington Management Group LLP now owns 86,988 shares of the company’s stock valued at $3,625,000 after acquiring an additional 8,757 shares in the last quarter. Artia Global Partners LP bought a new stake in Rapport Therapeutics in the 2nd quarter valued at $5,772,000. Finally, Bank of America Corp DE bought a new stake in Rapport Therapeutics in the 2nd quarter valued at $3,170,000.

Rapport Therapeutics News Roundup

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: RAP-219 achieved both Phase 2 endpoints in bipolar mania. The drug produced statistically significant placebo-adjusted improvements in mania measures, and Rapport plans to advance it into Phase 3. The results could substantially expand RAP-219’s market opportunity beyond epilepsy. Rapport Therapeutics Phase 2 results
• Positive Sentiment: Analysts remain bullish and several raised price targets. JonesTrading increased its target to $82, BTIG Research to $89 and Raymond James to $86, while HC Wainwright maintained a Buy rating. The average analyst target is approximately $68.36, implying substantial upside from recent levels. BTIG Research price target increase
• Positive Sentiment: Company insiders made roughly $1.57 million of open-market purchases. CFO Troy Ignelzi bought 5,500 shares, while directors Steven Paul, John Maraganore, Wendy Young and Paul Silva also purchased shares. The concentrated buying may signal management confidence after the clinical update. Rapport Therapeutics insider buying
• Neutral Sentiment: A valuation analysis argues that RAPP could be approximately 62% below fair value following the Phase 2 data, supporting the bullish case but relying on assumptions about Phase 3 success, approval and future commercialization. Rapport Therapeutics fair value analysis
• Negative Sentiment: Investors still face substantial execution risk. Commentary suggested some portions of the bipolar-mania data narrowly met expectations, potentially limiting enthusiasm after the initial rally. Rapport is also unprofitable, recently missed quarterly EPS estimates and is forecast to post a full-year loss of about $4.09 per share. The shares remain far below their 52-week high and below their 50-day and 200-day moving averages. Rapport Therapeutics bipolar data analysis

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for central nervous system disorders. The company’s approach is designed to selectively target receptor-associated proteins that regulate synaptic receptors, with the goal of improving therapeutic selectivity and reducing the side effects associated with broader-acting neurological medicines.

Rapport’s lead product candidate, RAP-219, is an orally administered small molecule being developed for neurological conditions, including focal epilepsy.